JAGSNPHARM closed at ₹242.06 on Sep 4, 2026. Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) trades on NSE/BSE. Market capitalisation is ₹1,594 Cr. The trailing P/E ratio is 35.60. It operates in the Healthcare sector.
JAGSNPHARM, Upmazing Score 85/100
Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM) scores 85 on Upmazing’s scoring engine, read from two independent layers: fundamentals filed with the exchange and end-of-day technicals. Below: each signal layer and the numbers behind it, marked with their sources.
Not built yetAI synthesis — not built yetOne paragraph that fuses JAGSNPHARM's latest filings with its price structure. Not built yet — nothing behind this card generates it today.
Past EOD returns redistributed — not a projection. LTCG shown at 12.5% beyond the ₹1.25 L/yr exemption (FY26 rules), indicative only, not tax advice; SIP units have mixed holding periods.
Frequently asked
auto-built per stock · FAQ schema
Once JAGSNPHARM's end-of-day history is ingested, this page shows its official exchange close, refreshed after each trading session, with the full price history on the Chart tab (split- and bonus-adjusted for NSE-primary series; BSE-primary series are shown as-traded). Upmazing does not stream live quotes, so every price-linked figure is anchored to the last close.
Where enough filed data exists, JAGSNPHARM carries an Upmazing Score, a 0-100 standing computed from its real fundamentals (growth, margins, leverage, returns) and end-of-day technicals. The Score tab breaks down every component, and says plainly when one can't be computed.
After each session with price data on record, JAGSNPHARM runs through Upmazing's end-of-day scanner library, covering momentum, trend, volatility, volume and fundamental checks. Scanners that fired on the latest session are listed on the Patterns tab with the exact rule each fired on.
Declared dividends, ex-dates and bonus or split history for JAGSNPHARM come from corporate-action records and appear here as they are ingested. Dividend yield is computed on trailing-12-month dividends at the last close.
Comparable companies for JAGSNPHARM are grouped by sector, then compared on revenue growth, ROE, ROCE, debt-to-equity and margins. The Peers tab shows the full side-by-side table, and where a sector is classified, the sector peers panel on this page links the largest sector-mates.
Market cap for JAGSNPHARM is computed from shares outstanding in the filed balance sheet, priced at the last close, and refreshed after each session. Where the balance-sheet input or a last close is missing, the cell shows a dash rather than an estimate.
The trailing 52-week high and low for JAGSNPHARM are derived from its end-of-day price history and appear in the key statistics on this page once a full year of sessions is on record. The full price chart lives on the Chart tab.
The filed balance sheet for JAGSNPHARM is presented on the Financials tab; for non-lenders that includes debt-to-equity, while banks and NBFCs read leverage through banking ratios instead.
Where JAGSNPHARM's shareholding pattern has been ingested, the Holdings tab tracks promoter, FII, mutual-fund, DII and public holding plus any promoter pledge, quarter by quarter from the disclosed filings.
Prices are official exchange end-of-day closes, refreshed after each trading session. Fundamentals, shareholding and corporate actions for JAGSNPHARM are parsed from official filings — quarterly results, shareholding disclosures and corporate-action records — as they are published.
Filed results · standalone · audited·as of Q1 2026-27partial data
Frequently Asked Questions
What is Jagsonpal Pharmaceuticals Limited's share price today?
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) closed at ₹242.06 on 2026-09-04.
Which sector does Jagsonpal Pharmaceuticals Limited belong to?
Jagsonpal Pharmaceuticals Limited is classified under sector 'Healthcare' / industry 'Pharmaceuticals & Biotechnology' per NSE's 4-tier classification.
What is Jagsonpal Pharmaceuticals Limited's PE ratio?
Jagsonpal Pharmaceuticals Limited's trailing PE ratio is 35.6x based on the latest filed earnings and market close.
